NASDAQ:IMA ImageneBio Q1 2026 Earnings Report $5.94 -0.06 (-1.00%) Closing price 06/25/2026 04:00 PM EasternExtended Trading$6.06 +0.12 (+2.02%) As of 06/25/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast ImageneBio EPS ResultsActual EPS-$0.95Consensus EPS -$0.70Beat/MissMissed by -$0.25One Year Ago EPSN/AImageneBio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImageneBio Announcement DetailsQuarterQ1 2026Date5/7/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile ImageneBio Earnings HeadlinesImageneBio, Inc. Common Stock (IMA) SEC FilingsJune 25 at 3:22 PM | nasdaq.comImageneBio Shareholders Back Directors and Governance ProposalsJune 17, 2026 | tipranks.com2,000 missiles didn't hit Iran. They hit China.Iran sold 90% of its oil to China. Venezuela secretly shipped 80% of its exports to the same buyer. Within 60 days, America cut both supply lines - starving China's AI power grid of the cheap, endless fuel it needs to compete. Now all that energy flows through a single American chokepoint: one company, 140,000 miles of steel, and no competition. Dylan Jovine has identified the stock at the center of this strategy, along with three ascending price targets.June 26 at 1:00 AM | Behind the Markets (Ad)ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New YorkMay 27, 2026 | globenewswire.comImageneBio (IMA) price target decreased by 18.75% to 13.26May 15, 2026 | msn.comImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program UpdateMay 7, 2026 | globenewswire.comSee More ImageneBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ImageneBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImageneBio and other key companies, straight to your email. Email Address About ImageneBioImageneBio (NASDAQ:IMA), a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.View ImageneBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings AloneMicron’s HBM Surge Could Redefine the AI Growth StoryCarnival's Second Quarter: Is the Stock Still Complicated?This Single Factor Is Holding Back Carvana’s Disruptive EdgePaychex Stock Looks Beaten Down, But Not BrokenWhy KB Home Could Reward Patient Investors LaterWashington’s Quantum Push Puts IBM and IonQ on the Throne Upcoming Earnings NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)ASML (7/15/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
